Prognostic significance of c-Met overexpression in cholangiocarcinoma
Author Information
Author(s): Miyamoto M, Ojima H, Iwasaki M, Shimizu H, Kokubu A, Hiraoka N, Kosuge T, Yoshikawa D, Kono T, Furukawa H, Shibata T
Primary Institution: National Cancer Center Research Institute
Hypothesis
The study aims to clarify the prognostic significance of c-Met overexpression and its association with clinicopathological factors in patients with cholangiocarcinoma.
Conclusion
c-Met overexpression is associated with EGFR expression and is a poor prognostic factor in cholangiocarcinoma.
Supporting Evidence
- c-Met overexpression was found in 57.9% of cholangiocarcinoma cases overall.
- High c-Met expression was significantly correlated with poor overall survival in intrahepatic cholangiocarcinoma.
- c-Methigh expression was an independent predictor of poor overall and disease-free survival in patients with intrahepatic cholangiocarcinoma.
Takeaway
This study found that high levels of a protein called c-Met in patients with a type of cancer called cholangiocarcinoma can mean they might not live as long.
Methodology
The study involved immunohistochemical analysis of c-Met expression in surgical specimens from 247 patients with cholangiocarcinoma, comparing clinicopathological factors and outcomes between c-Methigh and c-Metlow groups.
Limitations
The study did not perform multivariate analysis for extrahepatic cholangiocarcinoma due to lack of significant findings.
Participant Demographics
The study included 168 men and 79 women, aged 33 to 82 years, with a median age of 65 years.
Statistical Information
P-Value
0.0013
Confidence Interval
95% CI: 1.62–9.48
Statistical Significance
p=0.0013
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website